Inflammatory and Immune-Related Myopathies for Practical Clinical Decision-Making
Explains prognosis was given for inflammatory myopathy, the treatment for inflammatory myopathy, and might you add a steroid-sparing immunosuppressant in inflammatory myopathy in practical Neuromuscular Disorders care.
Duration
00:02:34
File size
1.56 MB
Practitioner-Guided Note
Use prognosis was given for inflammatory myopathy, the treatment for inflammatory myopathy, and might you add a steroid-sparing immunosuppressant in inflammatory myopathy to frame the working diagnosis and next step; use it to sharpen the differential and avoid a false label. Make the treatment for inflammatory myopathy the checkpoint that determines whether you escalate testing, narrow the differential, or change treatment.
Key Takeaways
Remaining twenty percent either fail to respond or experience worsening symptoms; About forty percent of individuals achieve complete remission after treatment, and another forty percent experience a partial remission or significant improvement; For recurrent or highly resistant cases, monthly intravenous immunoglobulin at a dose of two grams per kilogram per month can be introduced; If the case is refractory or you need steroid-sparing options, immunosuppressants like mycophenolate, azathioprine, or methotrexate are used; Standard approach is high-dose steroids, up to roughly one hundred milligrams daily, followed by a long course and a very slow taper